CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the sale, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at approximately $11,952,336.78. This trade represents a 3.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, March 16th, Samarth Kulkarni sold 10,349 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $48.26, for a total value of $499,442.74.
• On Wednesday, March 11th, Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.80, for a total value of $517,334.40.
• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.58, for a total value of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total transaction of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Price Performance

CRSP stock opened at $46.43 on Wednesday. The stock has a market cap of $4.46 billion, a price-to-earnings ratio of -7.12 and a beta of 1.72. The company has a 50 day simple moving average of $52.89 and a 200 day simple moving average of $57.02. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business’s quarterly revenue was down 97.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.01) EPS. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on CRSP shares. Chardan Capital increased their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. TD Cowen boosted their price target on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Needham & Company LLC upped their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 13th. Morgan Stanley reiterated an “underweight” rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. Finally, Evercore reiterated an “outperform” rating and set a $74.00 target price on shares of CRISPR Therapeutics in a research report on Friday, February 13th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $64.53.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Mcguire Capital Advisors Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. acquired a new stake in CRISPR Therapeutics in the fourth quarter worth $26,000. Optiver Holding B.V. grew its stake in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after buying an additional 210 shares during the period. Thompson Investment Management Inc. acquired a new stake in CRISPR Therapeutics in the third quarter valued at approximately $33,000. Finally, Strategic Advocates LLC acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at $34,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.